Mit Magzter GOLD unbegrenztes Potenzial nutzen
Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur
Versuchen GOLD - Frei
Does US cancer drug nod make Cipla attractive?
Mint Chennai
|April 18, 2025
Cipla, which makes HIV, respiratory and cancer drugs, is targeting North America with generic launches
Cipla Ltd's shares have surged 6% since last week when it announced the final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug. Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs loom?
"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."
Diese Geschichte stammt aus der April 18, 2025-Ausgabe von Mint Chennai.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Mint Chennai
Mint Chennai
Is America’s economy turning into a casino? Both yes and no
Americans are taking too many bad risks and too few good ones
3 mins
November 20, 2025
Mint Chennai
Global reset done, TVS supply chain unit eyes margin boost
TVS Supply Chain Solutions (SCS), whose wafer-thin margins and weak post-IPO performance have dampened investor sentiment since its 2023 debut, is looking to reset expectations after a major overhaul of its overseas operations.
2 mins
November 20, 2025
Mint Chennai
A fresh perspective on abstraction in art
A new exhibition in Mumbai showcases different approaches to abstraction by artists like Zarina, Seher Shah and Mehlli Gobhai
3 mins
November 20, 2025
Mint Chennai
A Gustav Klimt portrait shatters art records
Portrait of Elisabeth Lederer was sold at Sotheby's for $236.4 million
2 mins
November 20, 2025
Mint Chennai
Exide's dual bet: Can lithium-ion offset a weakening core?
Exide Industries Ltd is struggling to fuel its core lead-acid business while simultaneously turning its capex-heavy lithium-ion venture into a viable second growth engine.
1 mins
November 20, 2025
Mint Chennai
The crypto trades that amplified gains are now turbocharging losses
The rally in crypto prices this year was boosted by a large heap of debt, with traders using leverage to amplify their gains.
3 mins
November 20, 2025
Mint Chennai
Sebi mulls easing FPI trade settlement
The move would reduce costs for FPIs, says Sebi chairperson Tuhin Kanta Pandey.
1 min
November 20, 2025
Mint Chennai
Samsung India logs double-digit growth
Samsung India Electronics said it has clocked a double digit growth in its revenue from operations of over 11% to ₹1.11 trillion in the financial year ended March 2025.
1 min
November 20, 2025
Mint Chennai
BSNL dials vendors for a fix as regulator flags weak signal
State-owned Bharat Sanchar Nigam Ltd (BSNL) has flagged weak transmission signals at thousands of its new 4G towers—an issue behind call drops and slower data speeds—at a time when the operator is attempting a long-awaited turnaround backed by the government's successive revival packages.
1 mins
November 20, 2025
Mint Chennai
RP-Sanjiv Goenka enters luxe fashion with FSP stake buy
PSG Ventures Ltd, part of the RP-Sanjiv Goenka Group, on Wednesday approved the acquisition of a 40% stake in FSP Design Pvt. Ltd, the company behind the luxury fashion label Falguni Shane Peacock (FSP), is marking its formal entry into India’s luxury apparel and lifestyle market.
1 mins
November 20, 2025
Listen
Translate
Change font size